Technogym S.p.A. (BIT:TGYM)
14.36
+0.04 (0.28%)
Aug 13, 2025, 5:35 PM CET
ASLAN Pharmaceuticals Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 96.72 | 87.04 | 73.64 | 63.59 | 63.07 | 36 | Upgrade |
Depreciation & Amortization | 43.41 | 41.9 | 37.14 | 33.22 | 29.67 | 28.91 | Upgrade |
Other Amortization | 9.4 | 9.4 | 8.43 | 7.14 | 6.74 | 5.76 | Upgrade |
Asset Writedown & Restructuring Costs | 0.45 | 0.45 | 0.15 | 0.02 | 0.03 | 0.44 | Upgrade |
Loss (Gain) on Equity Investments | -0.03 | -0.07 | -4.4 | -1.77 | -15.35 | -0.88 | Upgrade |
Provision & Write-off of Bad Debts | 1.1 | 1.1 | 2.13 | 2.17 | 2.58 | 2.1 | Upgrade |
Other Operating Activities | 0.53 | 2.35 | 4.5 | 3.65 | 2.37 | 3.43 | Upgrade |
Change in Accounts Receivable | -12.82 | -12.41 | -5.64 | -5.62 | -24.12 | 49.71 | Upgrade |
Change in Inventory | -13.22 | -8.84 | 7.21 | 4.04 | -26.49 | -8 | Upgrade |
Change in Accounts Payable | 21.31 | 23.66 | -19.91 | 13.86 | 46.04 | -13.2 | Upgrade |
Change in Other Net Operating Assets | 13.23 | 10.82 | 3.59 | -8.06 | 8.59 | -2.04 | Upgrade |
Operating Cash Flow | 160.08 | 155.41 | 106.82 | 112.24 | 93.21 | 102.41 | Upgrade |
Operating Cash Flow Growth | 12.67% | 45.48% | -4.83% | 20.42% | -8.98% | -24.56% | Upgrade |
Capital Expenditures | -29.33 | -21.56 | -17.36 | -14.75 | -11.1 | -9.11 | Upgrade |
Sale of Property, Plant & Equipment | 2.32 | 2.48 | 0.82 | 0.33 | 0.69 | 1.33 | Upgrade |
Sale (Purchase) of Intangibles | -21.51 | -19.91 | -18.81 | -19.87 | -16.58 | -15.22 | Upgrade |
Sale (Purchase) of Real Estate | -0.06 | - | - | - | - | - | Upgrade |
Investment in Securities | - | - | 4.18 | - | 30.84 | - | Upgrade |
Other Investing Activities | 0.42 | 0.39 | 0.35 | 2.18 | 0.46 | 0.95 | Upgrade |
Investing Cash Flow | -49 | -38.61 | -30.82 | -32.11 | 4.32 | -22.05 | Upgrade |
Short-Term Debt Issued | - | 4.84 | 26.86 | 41.75 | - | - | Upgrade |
Long-Term Debt Issued | - | - | - | 4.01 | - | 50 | Upgrade |
Total Debt Issued | 34.84 | 4.84 | 26.86 | 45.76 | - | 50 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | -52.5 | -0.41 | Upgrade |
Long-Term Debt Repaid | - | -14.4 | -22.8 | -64.03 | -32.25 | -31.47 | Upgrade |
Total Debt Repaid | -23.59 | -14.4 | -22.8 | -64.03 | -84.75 | -31.88 | Upgrade |
Net Debt Issued (Repaid) | 11.26 | -9.56 | 4.06 | -18.27 | -84.75 | 18.12 | Upgrade |
Issuance of Common Stock | 1.33 | 1.11 | 0.21 | - | - | - | Upgrade |
Repurchase of Common Stock | - | -13.13 | -6.92 | - | - | - | Upgrade |
Common Dividends Paid | -157.8 | -55.16 | -51.32 | -32.17 | -44.29 | - | Upgrade |
Other Financing Activities | 1.8 | 3.71 | 3.04 | -0.35 | 1.77 | -5.75 | Upgrade |
Financing Cash Flow | -143.41 | -73.02 | -50.94 | -50.8 | -127.27 | 12.36 | Upgrade |
Foreign Exchange Rate Adjustments | -3.66 | 0.2 | -5.69 | 1.72 | 1.98 | -5.07 | Upgrade |
Miscellaneous Cash Flow Adjustments | 0 | - | - | 0 | - | 0 | Upgrade |
Net Cash Flow | -35.99 | 43.98 | 19.37 | 31.05 | -27.76 | 87.65 | Upgrade |
Free Cash Flow | 130.75 | 133.84 | 89.46 | 97.5 | 82.11 | 93.3 | Upgrade |
Free Cash Flow Growth | 2.55% | 49.61% | -8.24% | 18.73% | -11.99% | -18.47% | Upgrade |
Free Cash Flow Margin | 13.65% | 14.85% | 11.07% | 13.51% | 13.43% | 18.30% | Upgrade |
Free Cash Flow Per Share | 0.66 | 0.67 | 0.45 | 0.48 | 0.41 | 0.46 | Upgrade |
Cash Income Tax Paid | 45.43 | 34.81 | 24.36 | 22.28 | 14.33 | 15.98 | Upgrade |
Levered Free Cash Flow | 121.74 | 112.21 | 78.9 | 107.71 | 9.06 | 75.14 | Upgrade |
Unlevered Free Cash Flow | 124.49 | 112.79 | 79.36 | 108.23 | 9.6 | 75.73 | Upgrade |
Change in Working Capital | 8.49 | 13.23 | -14.76 | 4.22 | 4.02 | 26.48 | Upgrade |
Updated Aug 6, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.